Evolent Health, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Evolent Health, Inc. on September 23, 2025. The filing discloses a reaffirmation of financial guidance for the third quarter and full year 2025, alongside the announcement of a strategic divestiture of a subsidiary.
Key Financial Metrics and Guidance
The Company reaffirmed its non-GAAP guidance for the period ending September 30, 2025, and the full fiscal year 2025. These figures exclude the impact of the divestiture of ECP Holding Company.
| Period | Revenue Guidance | Adjusted EBITDA Guidance |
|---|---|---|
| Q3 2025 (Three months ended Sep 30) | $460 million - $480 million | $34 million - $42 million |
| Full Year 2025 | $1.85 billion - $1.88 billion | $140 million - $165 million |
The filing does not provide specific historical revenue, profit, cash flow, or debt figures for the current or prior periods, as this is a current report focused on forward-looking guidance and material events.
Material Changes and Corporate Events
On September 23, 2025, Evolent Health LLC entered into a Stock Purchase Agreement to divest Evolent Care Partners Holding Company, Inc. ("ECP Holding Company") to Privia Management Company, LLC.
- Purchase Price: $100 million, subject to customary closing adjustments.
- Contingent Payment: Up to $13 million, subject to the achievement of certain post-closing metrics.
- Expected Closing: Fourth quarter of 2025, subject to customary conditions including state governmental approvals.
Outlook, Risks, and Management Commentary
Management noted that updated guidance will be provided following the close of the divestiture transaction. The Company stated it cannot meaningfully reconcile non-GAAP Adjusted EBITDA guidance to net income due to the inability to forecast significant reconciling items without unreasonable effort. These items may include transaction-related costs, loss on debt extinguishment, changes in fair value of contingent consideration, and stock-based compensation.
The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks discussed in the Company's 2024 Form 10-K and 2025 Form 10-Q filings.
Key Facts for Investor Verification
- Verify the final closing date of the ECP Holding Company divestiture and the final purchase price after adjustments.
- Monitor the achievement of metrics required to trigger the up to $13 million contingent payment.
- Review the updated financial guidance expected to be issued after the transaction closes.
- Assess the impact of the divestiture on the Company's future revenue streams and Adjusted EBITDA margins.